& Events
& Events
News
& Events
May 19, 2022 Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress
MONTREAL (CANADA) – May 19, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show […]
May 17, 2022 Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately. Mr. Vraniak’s career spans more than 20 years of financial and commercial experience […]
May 12, 2022 Inversago Pharma to participate to upcoming Bio€quity Europe 2022 to be held on May 16-18 in Milan, Italy and on May 23-24 virtually
MONTREAL (CANADA) – May 12, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer and Glenn D. Crater, MD, FCCP, Chief Medical Officer, will take part to the Presenting Company Class of 2022 at Bio€quity Europe. […]
Apr 29, 2022 Inversago Pharma to participate in Life Science companies and investors networking event organized by Torys
MONTREAL (CANADA) – April 29, 2022 – Inversago Pharma Inc., a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer, will take part to one-on-one meetings with investors during Torys’ Life Science networking event. The event will take place on Sunday, May 1, […]
